21 July 2024 : Clinical Research
Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib
Jie Gao1BCE, Shu Liu2BCE, Shao-Jun Li1BCE, Rui Wang3E, Zeng-Hui Meng1AE, Xiang-Shuo Kong2AE*DOI: 10.12659/MSM.944526
Med Sci Monit 2024; 30:e944526
Table 1 Model parameters: baseline values, ranges, and references for sensitivity analysis.
| Variables | Baseline value | Low | High | References |
|---|---|---|---|---|
| Log-logistic OS survival model with HAIC-FO | θ=0.0066, κ=1.9183 | / | / | [1] |
| Weibull OS survival model with sorafenib | λ=0.0137, γ=1.8381 | / | / | [1] |
| Log-logistic PFS survival model with HAIC-FO | θ=0.0382, κ=1.5474 | / | / | [1] |
| Log-normal PFS survival model with sorafenib | μ=1.4528, σ=0.8132 | / | / | [1] |
| Drug costs, $/cycle | ||||
| Oxaliplatin | 426 | 340 | 511 | [2] |
| Fluorouracil | 524 | 419 | 629 | [2] |
| Leucovorin | 12 | 10 | 15 | [2] |
| HAIC | 1850 | 1480 | 2220 | [2] |
| Sorafenib | 2350 | 1880 | 2820 | [2] |
| TACE | 1929 | 1543 | 2315 | [3] |
| Regorafenib | 1910 | 1528 | 2292 | [4] |
| Nivolumab | 6372 | 5097 | 7646 | [4] |
| AEs cost, $/event | ||||
| Elevated AST | 43.31 | 34.648 | 51.972 | [2] |
| Neutropenia | 83.87 | 67.096 | 100.644 | [2] |
| Fatigue | 3.64 | 2.912 | 4.368 | [5] |
| Hypertension | 44.88 | 35.904 | 53.856 | [5] |
| Thrombocytopenia | 2072.18 | 1657.744 | 2486.616 | [6] |
| PFD | 0.76 | 0.61 | 0.91 | [4] |
| PD | 0.68 | 0.54 | 0.82 | [4] |
| AEs disutility | ||||
| Elevated AST | 0 | 0 | 0 | [2] |
| Neutropenia | 0.09 | 0.072 | 0.108 | [2] |
| Fatigue | 0.07 | 0.056 | 0.084 | [7] |
| Hypertension | 0.04 | 0.032 | 0.048 | [7] |
| Thrombocytopenia | 0.05 | 0.04 | 0.06 | [6] |
| 0.03 | 0 | 0.05 | [4] | |
| Subsequent treatment after HAIC-FO | 0.19 | 0.1536 | 0.2304 | [1] |
| Subsequent treatment after Sorafenib | 0.31 | 0.2488 | 0.3732 | [1] |
| HAIC-FO: Grade ≥3 AEs | ||||
| Elevated AST | 0.109 | 0.0872 | 0.1308 | [1] |
| Neutropenia | 0.078 | 0.0624 | 0.0936 | [1] |
| Fatigue | 0 | 0 | 0 | [1] |
| Hypertension | 0 | 0 | 0 | [1] |
| Thrombocytopenia | 0.109 | 0.0872 | 0.1308 | [1] |
| Sorafenib: Grade ≥3 AEs | ||||
| Elevated AST | 0.031 | 0.0248 | 0.0372 | [1] |
| Neutropenia | 0.062 | 0.0496 | 0.0744 | [1] |
| Fatigue | 0.062 | 0.0496 | 0.0744 | [1] |
| Hypertension | 0.101 | 0.0808 | 0.1212 | [1] |
| Thrombocytopenia | 0.023 | 0.0184 | 0.0276 | [1] |
| OS – overall survival; PFS – progression-free survival; HAIC-FO – hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin; TACE – transarterial chemoembolization; AE – adverse event; AST – aspartate aminotransferase; PFD – progression-free disease; PD – progressed disease; QALYs – quality-adjusted life-years; ICER – incremental cost-effectiveness ratio. References: [1] PMID: 34905388 DOI: 10.1200/JCO.21.01963; [2] PMID: 33767976 DOI: 10.3389/fonc.2021.562135; [3] PMID: 29621988 DOI: 10.1186/s12885-018-4308-7; [4] PMID: 37678272 DOI: 10.1097/JS9.0000000000000683; [5] PMID: 30087583 DOI: 10.1186/s12962-018-0112-0; [6] PMID: 29878848 DOI: 10.2217/fon-2018-0321; [7] PMID: 26990789 DOI: 10.1111/ajco.12477. | ||||